<DOC>
	<DOCNO>NCT00648284</DOCNO>
	<brief_summary>The primary objective study ass total CV risk patient type 2 diabetes also assess impact rosiglitazone total CV risk parameter metabolic syndrome .</brief_summary>
	<brief_title>Cardiovascular ( CV ) Risk Evaluation In Type 2 Diabetes Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Patients diabetes type 2 physician decide prescribe AVANDIA good control condition Have sign informed consent Patients ALT &gt; 2.5x normal value With heart failure symptom With diagnosis angina pectoris stable angina demand continuous treatment nitrate With recent myocardial infarction ( &lt; 6 month ) With severe renal disfunction Pregnant lactating plan pregnant study Under investigational drug treatment Alcoholic drug abuser</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>CV risk</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>AVANDIA</keyword>
</DOC>